Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

Uncovering novel therapeutic targets using induced pluripotent stem cells derived from acute myeloid leukemia patient cells

EF 2023-24

Résumé
Acute myeloid leukemia (AML) is a complex cancer that causes a build-up of immature blasts in the blood instead of producing healthy blood cells to fight infection and transport oxygen. Most patients respond to current therapies, but the majority go on to relapse and succumb to the disease. Thus, new therapies are needed. The discovery of new drugs is difficult as each patient responds differently and models of AML for individual AML patients is expensive and not predictive. The Nobel prize-winning ability to reprogram a specialized cell back to a primitive stem cell state may provide a revolutionary way to model and study AML on a patient-by-patient specific basis. Our lab has recently developed methods to create a library of AML patient cells trapped in the stem cell state that allows us to have an unlimited number of cells to study AML disease for individuals. Using this cutting-edge technology, we will use these AML stem cells to make leukemic cells tailored to each patient and test how the genetic makeup of the resulting cancer cells responds to specific drugs, both alone and in combination, in the laboratory. This innovative approach holds the promise of predicting drug responses in a personalized manner for each patient in a timely and cost-effective way. The goal is to establish a connection between individual patient genetics to their drug responses, with the ultimate aim of administering precisely tailored drugs during chemotherapy in the hopes of preventing relapse entirely in AML patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
506310
Name
Qiao Amy
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Uncovering novel therapeutic targets using induced pluripotent stem cells derived from acute myeloid leukemia patient cells
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia (Aml); Aml Ipscs; Clonal Hematopoiesis; Disease Relapse; Drug Sensitivity Screening; Hematopoietic Differentiation; Induced Pluripotent Stem Cells (Ipscs); Leukemic Progenitor Cells; Reprogramming; Stem Cells
Abstract
Acute myeloid leukemia (AML) is a complex cancer that causes a build-up of immature blasts in the blood instead of producing healthy blood cells to fight infection and transport oxygen. Most patients respond to current therapies, but the majority go on to relapse and succumb to the disease. Thus, new therapies are needed. The discovery of new drugs is difficult as each patient responds differently and models of AML for individual AML patients is expensive and not predictive. The Nobel prize-winning ability to reprogram a specialized cell back to a primitive stem cell state may provide a revolutionary way to model and study AML on a patient-by-patient specific basis. Our lab has recently developed methods to create a library of AML patient cells trapped in the stem cell state that allows us to have an unlimited number of cells to study AML disease for individuals. Using this cutting-edge technology, we will use these AML stem cells to make leukemic cells tailored to each patient and test how the genetic makeup of the resulting cancer cells responds to specific drugs, both alone and in combination, in the laboratory. This innovative approach holds the promise of predicting drug responses in a personalized manner for each patient in a timely and cost-effective way. The goal is to establish a connection between individual patient genetics to their drug responses, with the ultimate aim of administering precisely tailored drugs during chemotherapy in the hopes of preventing relapse entirely in AML patients.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Qiao, Amy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~